Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback